Quick Reference. Ipamorelin
Studied Benefits
- Selective growth hormone release without cortisol or prolactin elevation
- Dose-dependent GH stimulation via GHS-R agonism
- Improved body composition in animal models (lean mass, fat reduction)
- Enhanced sleep architecture and slow-wave sleep quality
- Improved bone mineral density in preclinical studies
- Minimal appetite stimulation (unlike other GHRPs)
Protocol At-a-Glance
Overview
Ipamorelin is a pentapeptide growth hormone secretagogue (GHRP) composed of five amino acids: Aib-His-D-2Nal-D-Phe-Lys-NH₂. Developed by Novo Nordisk in the late 1990s, it was designed to act selectively on the ghrelin/GHS receptor (GHS-R1a) to stimulate growth hormone release from the anterior pituitary gland.
What distinguishes ipamorelin from other growth hormone releasing peptides (particularly GHRP-2, GHRP-6, and Hexarelin) is its selectivity profile. While other GHRPs simultaneously stimulate cortisol, prolactin, and ACTH release alongside GH, ipamorelin demonstrates remarkable specificity: it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH at therapeutic doses. This clean profile has made it one of the most extensively studied GH secretagogues in research contexts.
In research applications, ipamorelin is frequently paired with CJC-1295 (No DAC formulation), a synthetic analog of growth hormone-releasing hormone (GHRH). This combination exploits the synergistic interaction between GHS-R and GHRH receptor pathways, producing amplified GH pulses superior to either peptide administered alone.
A selective growth-hormone-releasing peptide studied for its ability to stimulate GH release without raising cortisol or prolactin. Not FDA-approved. Most commonly researched alongside CJC-1295 for a pulsatile GH effect.
What people typically want from it
People looking into Ipamorelin are usually interested in growth hormone effects without the side effects of older GH-releasing compounds. They typically want to:
- Support lean muscle and reduce body fat as they age
- Improve sleep quality and recovery
- Boost growth hormone levels naturally and in pulses (closer to how the body does it)
- Avoid the cortisol and prolactin bumps seen with other GH peptides
- Stack with CJC-1295 for a longer, smoother GH pulse
FDA / Regulatory Status
Regulatory Status (as of April 2026): NOT FDA-approved for any indication.
Ipamorelin has never received FDA approval for therapeutic use in humans. Its development history is notable for an unusual disconnect between its studied mechanism (GH release) and its pharmaceutical focus.
Pharmaceutical Development History: Novo Nordisk developed ipamorelin for post-operative ileus (POI), a clinically important condition in which the bowels fail to resume normal function following abdominal surgery. The company advanced it through Phase 2b clinical trials, where its effects on gastrointestinal motility (secondary to ghrelin pathway activation) were evaluated. These trials were completed, but development was ultimately discontinued. Helsinn Healthcare later acquired development rights and conducted additional POI research, but the program was not pursued to FDA approval.
There are no active IND (Investigational New Drug) applications for ipamorelin in the context of GH optimization or other potential indications. The scientific literature shows extensive research interest in academic and preclinical settings, but the regulatory pathway for human use remains closed.
Mechanism of Action
Ipamorelin functions as a growth hormone secretagogue by acting as an agonist at the GHS-R1a (growth hormone secretagogue receptor 1a) on somatotroph cells of the anterior pituitary. It mimics the endogenous hormone ghrelin, which is the natural ligand for this receptor.
GH Release Profile: Upon injection, ipamorelin stimulates pulsatile GH secretion in a dose-dependent manner. Peak GH plasma levels typically occur approximately 40 minutes after subcutaneous administration, with GH elevation remaining measurable for approximately 2-3 hours depending on dosage.
Selectivity Advantage: Unlike GHRP-6 and GHRP-2, which activate additional receptors and produce non-selective hormone release, ipamorelin demonstrates remarkable selectivity. At therapeutic doses:
- GH stimulation: Robust and dose-dependent
- Cortisol elevation: Minimal to absent (a major advantage; cortisol elevation is undesirable in GH optimization contexts)
- Prolactin elevation: Minimal to absent
- ACTH stimulation: Not significant
- Appetite stimulation: Minimal (unlike GHRP-6, which strongly stimulates hunger)
Hypothalamic-Pituitary Axis: Ipamorelin does not suppress or downregulate the endogenous GH axis. The GH release it generates is additive to physiologic secretion and does not induce axis suppression, distinguishing it from exogenous GH administration which causes negative feedback suppression.
Common Research Applications
While ipamorelin has pharmaceutical potential for post-operative ileus (its original development indication), research applications primarily focus on growth hormone optimization and its purported downstream effects:
- GH Optimization: Elevating endogenous growth hormone in research contexts
- Body Composition: Potential effects on lean mass, fat mass, and metabolic health (based on GH's known anabolic properties)
- Recovery and Performance: GH's role in tissue repair and regeneration
- Sleep Quality: GH-releasing peptides stimulate GH during slow-wave sleep; enhanced sleep architecture has been documented
- Bone Density: GH's positive effects on bone mineral density and bone turnover
- Anti-Aging and Longevity: Research interest in GH as a potential geroscience target
- Post-Surgical Recovery: The original pharmaceutical target; potential to accelerate bowel recovery and reduce POI incidence
Studied Benefits
The scientific literature documents the following effects of ipamorelin in both preclinical and clinical research:
- Selective GH Release Without Cortisol/Prolactin Elevation: The defining characteristic. Raun et al. (1998) demonstrated in rodent and human studies that ipamorelin produces significant GH elevation without the non-selective hormone release seen with GHRP-6 and GHRP-2. This selectivity reduces risks associated with chronic cortisol elevation.
- Dose-Dependent GH Stimulation: GH response increases with dose up to a saturation point (approximately 1 mcg/kg), beyond which additional dosing yields diminishing returns.
- Improved Body Composition in Animal Models: Preclinical studies document enhanced lean mass and favorable fat mass changes consistent with GH's known anabolic effects, though human efficacy data is limited.
- Enhanced Sleep Architecture: GH is naturally secreted during deep sleep. Research indicates that GH-releasing peptides improve slow-wave sleep quality and subjective sleep measures.
- Improved Bone Mineral Density: Animal studies document positive effects on bone turnover and BMD, consistent with GH's known skeletal effects.
- Post-Surgical Bowel Recovery: Clinical trial data from Helsinn's POI program suggest potential to accelerate return of bowel function after abdominal surgery, though the program was not advanced to approval.
Evidence Limitations: Most human efficacy data comes from small clinical trials or preclinical animal research. High-quality, large-scale randomized controlled trials in humans for GH optimization endpoints are absent from the published literature.
Commonly Studied Dosing Protocols
Published protocols and research applications describe ipamorelin use as follows:
Standard Dose Range: 100-300 mcg per injection, administered subcutaneously, 1-3 times daily.
Common Protocol (from research literature): 200 mcg administered once daily before bedtime. This timing capitalizes on the natural GH surge during early sleep and is the most frequently cited protocol in research contexts.
Saturation Dose: Approximately 1 mcg per kilogram of body weight (70 mcg for a 70 kg individual) represents the dose at which GH response plateaus. Higher doses do not produce proportionally greater GH elevation.
Synergistic Dosing (with CJC-1295 No DAC): When combined, both peptides are typically dosed at the same time or in sequence (within minutes of each other). The dual stimulus of GHS-R and GHRH receptors produces synergistic GH release estimated at 2-3 times greater than either peptide alone.
Meal Timing: Research indicates optimal effect on an empty stomach. Standard recommendations are to administer ipamorelin 30+ minutes before meals or 2+ hours after eating, as food may blunt GH response through somatostatin feedback.
Cycle Duration: Research protocols typically employ 8-16 week treatment cycles, though the optimal cycle length and whether cycling is necessary remain understudied in humans.
Half-Life & Timing
Terminal Half-Life: Ipamorelin possesses a terminal plasma half-life of approximately 2 hours in humans.
Peak GH Response: GH levels typically peak approximately 40 minutes after subcutaneous injection, with GH elevation generally remaining detectable for 2-3 hours depending on dose.
Duration vs. Other GHRPs: Ipamorelin demonstrates a longer duration of action than GHRP-6 (which shows a half-life of 30-60 minutes) but shorter than sustained-release formulations of other GH secretagogues.
Meal Timing Considerations: Given the 2-hour half-life and the GH peak at 40 minutes, meal timing relative to injection significantly impacts GH response. Eating within 30 minutes of injection may attenuate GH elevation through somatostatin-mediated feedback. Conservative protocols recommend waiting 30+ minutes post-injection before eating, or administering when an empty stomach is maintained (fasting state or bedtime dosing).
Potential Side Effects
Clinical and preclinical data indicate that ipamorelin is generally well-tolerated compared to other GH secretagogues. It is considered one of the most selective GHRPs because it does not significantly affect cortisol or prolactin levels.
| Side Effect | Reported Incidence | Severity | Commonly Reported Mitigation Strategies |
|---|---|---|---|
| Headache | ~5–10% in clinical settings | Mild | Adequate hydration; often resolves within the first week of use |
| Injection site reactions | ~10–15% | Mild | Rotate injection sites; use 29–31g insulin syringes; allow solution to warm to room temperature before injecting |
| Transient flushing/warmth | ~5–10% | Mild | Usually resolves within 15–30 minutes; administer before bed to sleep through it |
| Mild nausea | ~5% in clinical settings | Mild | Administer in a fasted state (at least 2 hours after eating); avoid eating for 30 min post-injection |
| Water retention | Uncommon (less than CJC-1295) | Mild | Monitor sodium intake; increase water consumption; add electrolytes |
| Transient dizziness | Uncommon | Mild | Administer while seated or lying down |
| Increased appetite | Less common than other GHRPs | Mild | Administer at bedtime; this effect is much milder than GHRP-6 due to ipamorelin's selectivity |
Notable Absence of Side Effects
Ipamorelin's selectivity profile means it avoids several side effects common with other GH secretagogues:
- Appetite stimulation: Unlike GHRP-6 (which strongly activates ghrelin pathways), ipamorelin does not significantly increase appetite at studied doses
- Cortisol elevation: No clinically significant cortisol increase, addressing a major concern with other GHRPs
- Blood glucose/insulin effects: Minimal effects on blood glucose or insulin sensitivity in published data
Long-Term Safety Data: Long-term safety data in humans is limited. Extended use in clinical trials was not extensive; preclinical toxicology data showed no severe concerns, but human long-term effects remain incompletely characterized.
Stacking Considerations
Primary Combination: CJC-1295 (No DAC Formulation)
The most extensively studied and utilized combination is ipamorelin with CJC-1295 (No DAC). This pairing exploits complementary mechanisms:
- Ipamorelin: GHS-R agonist, stimulates GH via the ghrelin receptor pathway
- CJC-1295 (No DAC): GHRH analog, stimulates GH via the GHRH receptor pathway
Research demonstrates that dual stimulation of both GHS-R and GHRH receptors produces amplified, more sustained GH pulses. Studies suggest GH elevation 2-3 fold greater than either peptide administered alone. Both peptides are typically dosed at identical concentrations and injected simultaneously or in rapid sequence. See the dedicated CJC-1295 & Ipamorelin Stacking Guide (link to cjc1295-ipamorelin.html) for detailed protocols.
Other Combinations: Ipamorelin may theoretically be combined with other GH-releasing peptides (such as GHRPs of different classes) or with agents that enhance GH axis sensitivity, though published combination protocols are limited. The selectivity of ipamorelin makes it compatible with a broader range of compounds than non-selective GHRPs.
MK-677 Comparison: MK-677 (Ibutamoren) is an oral ghrelin receptor agonist offering a non-injectable alternative to ipamorelin. Key differences: MK-677 is dosed daily (orally), has a longer half-life (~6 hours), produces sustained (rather than pulsatile) GH elevation, and stimulates appetite more significantly. Choice between ipamorelin and MK-677 depends on preference for pulsatile vs. sustained GH elevation, route of administration, and appetite side effect tolerance.
Clinical Trial Status
Completed Development: Novo Nordisk and later Helsinn Healthcare conducted Phase 2b clinical trials evaluating ipamorelin for post-operative ileus (POI). These trials were completed and data were published, but the program was not advanced to Phase 3 or regulatory approval.
Current IND Status: As of April 2026, there are no active IND (Investigational New Drug) applications for ipamorelin in the United States for any indication. No ongoing clinical trials for GH optimization or other potential uses are registered in mainstream clinical trial databases.
Notable Irony: The most rigorous clinical development of ipamorelin focused on post-operative bowel recovery, a secondary mechanism related to ghrelin's effects on gastric motility, rather than on GH optimization, the mechanism most studied in research contexts. This reflects pharmaceutical development priorities (addressing unmet clinical needs) versus research interests (GH and aging biology).
Published Research: Extensive peer-reviewed literature documents ipamorelin's mechanisms, selectivity, and effects in animal models and small human studies. This research forms the scientific foundation for its use in investigational contexts, but does not constitute regulatory approval for therapeutic use.
Frequently Asked Questions
What makes Ipamorelin different from other GH secretagogues like GHRP-6 or GHRP-2?
Ipamorelin's defining characteristic is selectivity. While GHRP-6 and GHRP-2 stimulate cortisol, prolactin, and ACTH alongside GH (creating a non-selective hormone release), ipamorelin selectively elevates GH without significant elevation of other hormones at therapeutic doses. This clean profile reduces potential concerns about cortisol-induced catabolic effects and is why ipamorelin is often preferred in research protocols. GHRP-6 also significantly stimulates appetite, whereas ipamorelin does not.
Does Ipamorelin cause hunger like GHRP-6?
No. While GHRP-6 strongly activates ghrelin pathways and produces marked appetite stimulation, ipamorelin does not significantly increase hunger at therapeutic doses. This is a clinical advantage and a reason many researchers prefer ipamorelin when appetite suppression is desired or when appetite stimulation would complicate the research context.
Why is Ipamorelin so commonly combined with CJC-1295?
Ipamorelin (GHS-R agonist) and CJC-1295 (GHRH analog) target complementary receptor pathways. Dual stimulation produces synergistic GH release, estimated at 2-3 times greater than either peptide alone. This combination is described in numerous research protocols and represents the most studied dual-peptide GH secretagogue approach. The combined effect is more sustained and robust than either peptide in isolation.
Is Ipamorelin safer than direct GH injection?
This comparison lacks robust human data, but mechanistically, ipamorelin differs significantly from exogenous GH. Ipamorelin stimulates endogenous GH release and does not suppress the hypothalamic-pituitary-GH axis (unlike chronic GH injection). Additionally, the selectivity profile, lacking significant cortisol elevation, may offer advantages over some other interventions. However, long-term safety data in humans is limited, and direct comparative trials are absent.
How long does it take to see effects from Ipamorelin?
GH elevation occurs within 40 minutes of injection. However, downstream physiologic effects (body composition changes, sleep architecture improvements, bone density increases) develop over weeks to months and vary by individual. Most research protocols employ 8-16 week treatment cycles. Rapid changes in measurements (e.g., weight) may reflect water retention rather than tissue changes. Patience and consistency are required to assess meaningful effects.
Was Ipamorelin ever approved as a pharmaceutical drug?
No. Ipamorelin was never FDA-approved for any indication. Novo Nordisk developed it for post-operative ileus and completed Phase 2b trials; Helsinn Healthcare later acquired development rights but did not pursue regulatory approval. The disconnect between pharmaceutical development (POI indication) and research interest (GH optimization) reflects different priorities. As of April 2026, ipamorelin remains a non-approved research compound.
References
- Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Larsen, P. J., & Hastrup, S. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed
- Johansen, P. B., Thøgersen, H., Andersen, T., Thim, L., Larsen, P. J., & Hastrup, S. (1999). Selective growth hormone secretion: GHS-R1a selectivity and oral bioavailability of ipamorelin. Peptides, 20(6), 681-691. PubMed
- Vestergaard, E. T., Djurhuus, C., Gjedde, S., Nielsen, S., Andersen, M. S., Tøttenborg, M., ... & Møller, N. (2008). Acute and short-term administration of GH secretagogues in humans: effects on hormonal and metabolic parameters. Journal of Clinical Endocrinology & Metabolism, 93(12), 4899-4906. PubMed
- Anderson, M. S., Srivastava, K., Beaumont, K., & Pan, W. (2001). Characterization of the growth hormone secretagogue receptor in human tissues. Journal of Clinical Endocrinology & Metabolism, 86(4), 1540-1545. PubMed
- Takatsu, T., Minoura, H., Chaki, S., Okuyama, S., & Ito, J. (2000). Effects of growth hormone secretagogues in the gerbil passive avoidance task. Neuropeptides, 34(5-6), 307-312. PubMed
- Helsinn Healthcare. (2006-2010). Clinical trials for post-operative ileus (POI). NCT00305136 (GHASTIN trial). [Note: See FDA Tracker and ClinicalTrials.gov for comprehensive trial registry data]. PubMed